Fujian Cosunter's Novel Hepatitis B Drug GST-HG141 Completes Patient Enrollment for Phase III Trial

Stock News

02/04

Fujian Cosunter Pharmaceutical Co.,Ltd. (300436.SZ) has announced that its innovative drug subsidiary, Fujian Cosunter Zhonglin Biotechnology Co., Ltd., has successfully completed patient enrollment for the Phase III clinical trial of its Class 1 innovative hepatitis B treatment, Nairuikewei (GST-HG141). A total of 578 participants have been enrolled in the study.

Following the completion of patient enrollment for the GST-HG141 Phase III clinical trial, the study will proceed according to the established clinical protocol and requirements. The drug must subsequently receive marketing approval from the National Medical Products Administration before it can be launched commercially.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1186369492"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186369492\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186369492?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 16:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186369492","market":"sg","top_or_hot":-1,"title":"Fujian Cosunter's Novel Hepatitis B Drug GST-HG141 Completes Patient Enrollment for Phase III Trial","media":"Stock News","content":"<p>Fujian Cosunter Pharmaceutical Co.,Ltd. (300436.SZ) has announced that its innovative drug subsidiary, Fujian Cosunter Zhonglin Biotechnology Co., Ltd., has successfully completed patient enrollment for the Phase III clinical trial of its Class 1 innovative hepatitis B treatment, Nairuikewei (GST-HG141). A total of 578 participants have been enrolled in the study.</p>\n<p>Following the completion of patient enrollment for the GST-HG141 Phase III clinical trial, the study will proceed according to the established clinical protocol and requirements. The drug must subsequently receive marketing approval from the National Medical Products Administration before it can be launched commercially.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fujian Cosunter's Novel Hepatitis B Drug GST-HG141 Completes Patient Enrollment for Phase III Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFujian Cosunter's Novel Hepatitis B Drug GST-HG141 Completes Patient Enrollment for Phase III Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-04 16:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fujian Cosunter Pharmaceutical Co.,Ltd. (300436.SZ) has announced that its innovative drug subsidiary, Fujian Cosunter Zhonglin Biotechnology Co., Ltd., has successfully completed patient enrollment for the Phase III clinical trial of its Class 1 innovative hepatitis B treatment, Nairuikewei (GST-HG141). A total of 578 participants have been enrolled in the study.</p>\n<p>Following the completion of patient enrollment for the GST-HG141 Phase III clinical trial, the study will proceed according to the established clinical protocol and requirements. The drug must subsequently receive marketing approval from the National Medical Products Administration before it can be launched commercially.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1186369492","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186369492","pubTimestamp":1770195467,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Fujian Cosunter Pharmaceutical Co.,Ltd. (300436.SZ) has announced that its innovative drug subsidiary, Fujian Cosunter Zhonglin Biotechnology Co., Ltd., has successfully completed patient enrollment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300436":"广生堂","BK0239":"医药制造","III":"信息服务","GST":"Gastar Exploration","BK4134":"信息科技咨询与其它服务"},"translate_title":"福建科顺特乙肝新药GST-HG141完成III期试验患者入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300436":1,"III":1,"GST":1},"content_text":"Fujian Cosunter Pharmaceutical Co.,Ltd. (300436.SZ) has announced that its innovative drug subsidiary, Fujian Cosunter Zhonglin Biotechnology Co., Ltd., has successfully completed patient enrollment for the Phase III clinical trial of its Class 1 innovative hepatitis B treatment, Nairuikewei (GST-HG141). A total of 578 participants have been enrolled in the study.\nFollowing the completion of patient enrollment for the GST-HG141 Phase III clinical trial, the study will proceed according to the established clinical protocol and requirements. The drug must subsequently receive marketing approval from the National Medical Products Administration before it can be launched commercially.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}